Question 1

How has Insilico’s Pharma.AI platform demonstrated measurable impact on drug discovery timelines and pipeline productivity?

Accepted Answer

Public benchmarks report that Insilico has nominated over 20 development candidates between 2021 and 2024, with recent filings showing an average 12–18‑month window from project start to preclinical candidate and only 60–200 molecules synthesized per program, and case studies of assets like ISM001‑055 reaching Phase I in about 30 months — substantially faster and leaner than the multi‑year, multi‑thousand‑compound trajectories that typify traditional discovery.

Question 2

What is Insilico’s regulatory and compliance posture if we use its outputs to support GxP development or regulatory submissions?

Accepted Answer

Insilico operates primarily as an R&D and clinical development platform rather than a regulated medical device for direct clinical decision support, so there is no public evidence of FDA or CE marking for its software as a medical device. When its models and outputs inform GxP activities, clinical trial design, or regulatory dossiers, sponsors typically need to treat them as supporting tools within existing quality systems and align documentation with applicable frameworks (for example, GxP, ICH, EMA/FDA expectations for model-informed drug development), ensuring independent scientific and regulatory review of assumptions, data, and methods.

Question 3

What implementation, integration, and ROI considerations should we plan for when adopting Insilico within our existing R&D technology stack?

Accepted Answer

Insilico is generally deployed as a cloud-based platform that integrates with internal R&D data sources, cheminformatics, and clinical development systems, which can require data harmonisation, security review, and configuration effort to align with existing pipelines. Reported benchmarks suggest that, when properly integrated, the platform may compress early discovery timelines and reduce the number of synthesized compounds per program, but organizations still need to define their own ROI framework and track metrics such as time-to-IND, cost per candidate, and success rates against their historical baselines.

Useful Links

Our Services

Contact Us